Japan-based Astellas Pharma Inc. (ALPMY) on Monday announced results from the Phase 3 ADMIRAL clinical trial comparing Xospata (gilteritinib) to salvage chemotherapy in adult patients with relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia or AML with a FLT3 mutation.
from RTT - Biotech https://ift.tt/2Vcn0xk
via IFTTT
No comments:
Post a Comment